FDG-PET and amyloid-PET imaging: The diverging paths

Current Opinion in Neurology

Volumn 27, Issue 4, 2014, Pages 405-413

  Perani, Daniela ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; amyloid burden; cerebral glucose metabolism; PET; radiotracers

Indexed keywords

AMYLOID PROTEIN; FLUORODEOXYGLUCOSE; TAU PROTEIN; AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; DISEASE COURSE; FUNCTIONAL NEUROIMAGING; GLUCOSE METABOLISM; HUMAN; IN VIVO STUDY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENILE PLAQUE; BRAIN; DIAGNOSTIC USE; METABOLISM; PATHOLOGY; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84904042877     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000109     Document Type: Review

References (68)

1. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2013; 9:e111-e194.
2. Frisoni GB, Bocchetta M, Ché telat G, et al. Imaging markers for Alzheimer disease: which vs how. Neurology 2013; 81:487-500.
3. Perani D, Schillaci O, Padovani A, et al. A survey of FDG-and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int 2014.
4. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9:1118-1127.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263-269.
6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270-279.
7. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:280-292.
8. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795-804.
9. Mosconi L, De Santi S, Brys M, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 2008; 63:609-618.
10. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9:119-128.
11. Ché telat G. Alzheimer disease: Ab-independent processes-rethinking preclinical AD. Nat Rev Neurol 2013; 9:123-124.
12. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013; 80:1347-1358.
13. Jack CR, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegenerationfirst profiles characterize incident amyloid PET positivity. Neurology 2013; 81:1732-1740.
14. Knopman DS, Jack CR, Wiste HJ, et al. Brain injury biomarkers are not dependent on b-amyloid in normal elderly. Ann Neurol 2013; 73:472-480.
15. Pimplikar SW, Nixon RA, Robakis NK, et al. Amyloid-independent mechanisms, in Alzheimer's disease pathogenesis. J Neurosci 2010; 30:14946-14954.
16. Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013; 108:21-43.
17. Mosconi L, Murray J, Tsui WH, et al. Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology 2014; 752-760.
18. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79:1094-1108.
19. Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013; 54:1420-1427.
20. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34:457-468.
21. Giacobini E, Gold G. Alzheimer disease therapy-moving from amyloid-b to tau. Nat Rev Neurol 2013; 9:677-686.
22. Mosconi L. Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies. Clin Transl Imaging 2013; 1:217-233.
23. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443:787-795.
24. Villain N, Desgranges B, Viader F, et al. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J Neurosci 2008; 28:6174-6181.
25. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36:747-751.
26. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci 2006; 7:278-294.
27. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82:239-259.
28. Royall DR, Palmer RF, Petrovitch H, et al. Modeling regional vulnerability to Alzheimer pathology. Neurobiol Aging 2012; 33:1556-1563.
29. Perani D. Functional neuroimaging of cognition. Handb Clin Neurol 2008; 88:61-111.
30. Dukart J, Mueller K, Villringer A, et al. Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease. Neuroimage Clin 2013; 3:84-94.
31. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008; 49:390-398.
32. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005; 62:1728-1733.
33. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007; 130:2616-2635.
34. Fouquet M, Desgranges B, Landeau B, et al. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain 2009; 132:2058-2067.
35. Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. NeuroImage 2009; 47:1196-1206.
36. Jagust W, Gitcho A, Sun F, et al. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 2006; 59:673-681.
37. Landau SM, Breault C, Joshi AD, et al. Amyloid-b imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013; 54:70-77.
38. Ni R, Gillberg PG, Bergfors A, et al. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain 2013; 136:2217-2227.
39. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65:1304-1309.
40. Knight WD, Okello AA, Ryan NS, et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011; 134:293-300.
41. Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136:844-858.
42. Laforce R, Rabinovici GD. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 2011; 3:31.
43. Vlassenko AG, Vaishnavi SN, Couture L, et al. Spatial correlation between brain aerobic glycolysis and amyloid-b (Ab) deposition. Proc Natl Acad Sci U S A 2010; 107:17763-17767.
44. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25:7709-7717.
45. Pike KE, Savage G, Villemagne VL, et al. b-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130:2837-2844.
46. Klunk WE. Amyloid imaging as a biomarker for cerebral b-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011; 32 (Suppl 1): S20-S36.
47. Villemagne VL, Pike KE, Ché telat G, et al. Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69:181-192.
48. Ché telat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin 2013; 2:356-365.
49. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18:351-357.
50. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011; 121:171-181.
51. Tauber C, Beaufils E, Hommet C, et al. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients. J Alzheimers Dis 2013; 36:311-320.
52. Della Rosa PA, Cerami C, Gallivanone F, et al. A Standardized [18F]-FDGPET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 2014. (in press).
53. Caroli A, Prestia A, Chen K, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med 2012; 53:592-600.
54. van Berckel BNM, Ossenkoppele R, Tolboom N, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 2013; 54:1570-1576.
55. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31:1275-1283.
56. Garibotto V, Borroni B, Kalbe E, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 2008; 71:1342-1349.
57. Rentz DM, Locascio JJ, Becker JA, et al. Cognition reserve, and amyloid deposition in normal aging. Ann Neurol 2010; 67:353-364.
58. Jack CR, Wiste HJ, Lesnick TG, et al. Brain b-amyloid load approaches a plateau. Neurology 2013; 80:890-896.
59. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12:357-367.
60. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72:578-586.
61. Furst AJ, Rabinovici GD, Rostomian AH, et al. Cognition glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging 2012; 33:215-225.
62. Edison P, Archer H, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease An [11C] PiB and [18F] FDG PET study. Neurology 2007; 68:501-508.
63. Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013; 70:1512-1519.
64. La Joie R, Perrotin A, Barré L, et al. Region-specific hierarchy between atrophy, hypometabolism, and b-amyloid (Ab) load in Alzheimer's disease dementia. J Neurosci 2012; 32:16265-16273.
65. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8:101-112.
66. Jagust WJ, Landau SM, For the Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E, not fibrillar b-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012; 32:18227-18233.
67. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11:1048-1056.
68. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-b-associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol 2012; 69:709-713.